Immunotherapy最新文献_第9页

Immunotherapy of endometrial cancer: a review of recent advances. 子宫内膜癌的免疫治疗：最新进展综述。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-03-18 DOI: 10.1080/1750743X.2026.2644799

Krešimir Tomić, Kristina Katić, Zoran Gatalica, Gordan Srkalović, Maja Pezer Naletilić, Eduard Vrdoljak, Semir Vranić

引用次数: 0

Immune checkpoint inhibitors in dedifferentiated chondrosarcoma: toward breaking therapeutic resistance. 去分化软骨肉瘤的免疫检查点抑制剂：朝着打破治疗耐药性的方向发展。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-04-03 DOI: 10.1080/1750743X.2026.2652485

Tarek Assi, Tania Moussa, Rebecca Ibrahim, Axel Le Cesne

引用次数: 0

Neoadjuvant immune checkpoint inhibitors for muscle-invasive urothelial carcinoma: a systematic review and meta-analysis. 新辅助免疫检查点抑制剂治疗肌肉侵袭性尿路上皮癌：系统回顾和荟萃分析。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-03-12 DOI: 10.1080/1750743X.2026.2643128

Ana Luíza Rocha Soares Menegat, Brenda Luana Rocha Soares Menegat, Luana Diniz Guerra Braz, Maria Victória Ferreira Piccoli, Thiago Gorayeb Rebelo, Francisco Cezar Aquino de Moraes

{"title":"Neoadjuvant immune checkpoint inhibitors for muscle-invasive urothelial carcinoma: a systematic review and meta-analysis.","authors":"Ana Luíza Rocha Soares Menegat, Brenda Luana Rocha Soares Menegat, Luana Diniz Guerra Braz, Maria Victória Ferreira Piccoli, Thiago Gorayeb Rebelo, Francisco Cezar Aquino de Moraes","doi":"10.1080/1750743X.2026.2643128","DOIUrl":"10.1080/1750743X.2026.2643128","url":null,"abstract":"Introduction: Muscle-invasive urothelial carcinoma (MIUC) represents one-quarter of cancers and carries morbidity and mortality. Although cisplatin neoadjuvant chemotherapy plus radical cystectomy improves survival, patients may be ineligible due to renal dysfunction or comorbidities. Immune checkpoint inhibitors (ICIs), established in metastatic disease, are emerging as neoadjuvant options.Methods: A systematic search of PubMed, Embase, and the Cochrane Library identified clinical trials evaluating ICIs in MIUC. Meta-analysis was conducted using a random-effects model. Statistical analyses were performed in R software (version 4.4.1), with p < 0.05 considered significant.Results: Eleven studies comprising 573 patients (82.02% male) were included. The pooled pathologic complete response (pCR) rate was 35% (95% CI: 31%-39%). Overall survival (OS), recurrence-free survival (RFS), and event-free survival (EFS) at 2 years were 85% (95% CI: 77%-90%), 78% (95% CI: 72%-83%), and 73% (95% CI: 66%-79%), respectively. Additionally, the incidence of grade ≥3 cardiovascular, hematological, and immune-related adverse events (AEs) was 3% (95% CI: 2%-6%), 16% (95% CI: 11%-23%), and 5% (95% CI: 3%-8%), respectively.Conclusions: Neoadjuvant ICIs demonstrate favorable efficacy and acceptable safety in MIUC, particularly among cisplatin-ineligible patients. Randomized trials are needed to confirm long-term oncological outcomes and establish their role in curative treatment.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD42025640278.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"139-155"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13094266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147432628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Conversion surgery after pembrolizumab for initially unresectable MSI-H small bowel adenocarcinoma: a case report and brief analysis. 派姆单抗治疗最初不可切除的MSI-H小肠腺癌后的转化手术：一例报告和简要分析。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-01-01 Epub Date: 2026-02-05 DOI: 10.1080/1750743X.2026.2626236

Yu Nakashima, Yukihiro Yokoyama, Kazuhiro Hiramatsu, Masahide Fukaya, Taro Aoba, Atsuki Arimoto, Hiromasa Yamashita, Yoshifumi Arai, Takehito Kato

{"title":"Conversion surgery after pembrolizumab for initially unresectable MSI-H small bowel adenocarcinoma: a case report and brief analysis.","authors":"Yu Nakashima, Yukihiro Yokoyama, Kazuhiro Hiramatsu, Masahide Fukaya, Taro Aoba, Atsuki Arimoto, Hiromasa Yamashita, Yoshifumi Arai, Takehito Kato","doi":"10.1080/1750743X.2026.2626236","DOIUrl":"10.1080/1750743X.2026.2626236","url":null,"abstract":"Small-bowel adenocarcinoma (SBA) is rare and often diagnosed at an advanced stage. We report the case of a 61-year-old man with locally advanced unresectable upper jejunal SBA secondary to metastatic lymph nodes involving the superior mesenteric artery. Initial chemotherapy with FOLFOX (oxaliplatin, fluorouracil, and folinic acid) was initiated; however, a microsatellite instability-high (MSI-H) status was identified, and the treatment was promptly switched to pembrolizumab. After four cycles, marked regression of the metastatic lymph nodes was observed, and conversion surgery was performed. Partial jejunectomy with lymphadenectomy was performed to achieve an R0 resection. Pathological examination revealed a moderately differentiated adenocarcinoma with extensive fibrosis in the metastatic lymph nodes, indicating a substantial response to immunotherapy. The patient remained disease-free for 9 months postoperatively. Additionally, a brief meta-analysis of 10 studies comprising 72 patients with MSI-H/mismatch repair-deficient SBA revealed an objective response rate to immune checkpoint inhibitors of 65.3%. This case highlights the potential of pembrolizumab for the curative resection of an initially unresectable MSI-H SBA.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"51-59"},"PeriodicalIF":2.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13060043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of antibiotics on survival outcomes and risk of gastritis/colitis in advanced-stage melanoma patients receiving immune checkpoint inhibitor therapy. 抗生素对接受免疫检查点抑制剂治疗的晚期黑色素瘤患者生存结局和胃炎/结肠炎风险的影响

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-01-01 Epub Date: 2026-02-10 DOI: 10.1080/1750743X.2026.2626241

Shannon L Bailey, Janmesh D Patel, Thomas Havighurst, Vincent Pozorski, Yusuf Mohamoud, Dahlia Tesfamichae, Elizabeth Dow-Hillgartner, Lindsey Jung, Alexander Birbrair, Vincent T Ma

{"title":"Impact of antibiotics on survival outcomes and risk of gastritis/colitis in advanced-stage melanoma patients receiving immune checkpoint inhibitor therapy.","authors":"Shannon L Bailey, Janmesh D Patel, Thomas Havighurst, Vincent Pozorski, Yusuf Mohamoud, Dahlia Tesfamichae, Elizabeth Dow-Hillgartner, Lindsey Jung, Alexander Birbrair, Vincent T Ma","doi":"10.1080/1750743X.2026.2626241","DOIUrl":"10.1080/1750743X.2026.2626241","url":null,"abstract":"Aim: To determine the impact of antibiotic spectrum of activity and exposure timing on survival outcomes and development of gastritis/colitis.Methods: We conducted a single-center, retrospective cohort study of 214 patients with advanced, metastatic, or unresectable melanoma treated with immune checkpoint inhibitors. Antibiotic exposure was classified by spectrum of activity (with and without anaerobic coverage) and antibiotic timing. Primary outcomes were the effect of antibiotic administration 30-days prior to starting ICI therapy and during ICI therapy on overall survival (OS) and progression-free survival (PFS).Results: Antibiotic exposure during ICI was associated with improved OS (HR: 0.57, 95% CI (0.35-0.92), p = 0.023). Use of antibiotics without anaerobic coverage was associated with improved PFS (HR: 0.53, 95% CI (0.32-0.87), p = 0.013), and OS (HR: 0.47, 95% CI (0.24-0.92), p = 0.026). There was a trend toward increased risk of gastritis/colitis with antibiotics without anaerobic coverage during ICI therapy, although this did not reach statistical significance (OR 2.08, 95% CI (0.43-5.46), p = 0.069).Conclusion: Antibiotic timing and spectrum of activity may be predictive of survival outcomes and risk of developing gastritis/colitis in ICI-treated patients with advanced-stage melanoma. Unlike previous studies, we found improved survival in patients receiving antibiotics during treatment and in those receiving antibiotics without anaerobic coverage.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"17-24"},"PeriodicalIF":2.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12962703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146149430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Friendly fire? A case of inadvertent reactivation and progression of chronic lymphocytic leukemia following the treatment of cutaneous squamous cell carcinoma with Cemiplimab - case report. 友好的火?慢性淋巴细胞白血病在用西米单抗治疗皮肤鳞状细胞癌后意外再激活和进展1例。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-01-01 Epub Date: 2026-02-06 DOI: 10.1080/1750743X.2026.2626238

Adewale A Fawole, Maen Hussein, Muna A AlShawabkeh

引用次数: 0

Comparison of treatment with GP2017 (an adalimumab biosimilar) and reference adalimumab in people with plaque psoriasis: a plain language summary of the ADACCESS trial. GP2017（一种阿达木单抗生物类似药）和参考阿达木单抗治疗斑块型银屑病患者的比较：ADACCESS试验的简单语言总结

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-01-01 Epub Date: 2026-02-18 DOI: 10.1080/1750743X.2026.2624291

Neil Betteridge, Andrew Blauvelt, Colin Edgerton, Jamie Fan, Davide Guerrieri, Laura Rose, Ines Brueckmann, Qingfeng Wang

引用次数: 0

Hydrogel-based strategies in cancer treatment: promising innovations to advance cytokine-induced killer (CIK) cell immunotherapy. 基于水凝胶的癌症治疗策略：推进细胞因子诱导的杀伤（CIK）细胞免疫治疗的有希望的创新。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-01-01 Epub Date: 2026-02-04 DOI: 10.1080/1750743X.2026.2626204

Xinyue Qin, Yinhao Chen, Di Wu, Amit Sharma, Ingo G H Schmidt-Wolf

引用次数: 0

Combination of anti-PD-1 treatment with chemotherapy in a patient with metaplastic breast cancer during lactation. 抗pd -1联合化疗治疗哺乳期化脓性乳腺癌1例。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-01-01 Epub Date: 2026-02-02 DOI: 10.1080/1750743X.2026.2623783

Jiaqing Song, Qinghong Yu, Hongting Wu, Ying Jin, Xiufei Gao

引用次数: 0

Symptoms, symptom burden, and influencing factors in patients treated with Nivolumab. 纳武单抗治疗患者的症状、症状负担和影响因素

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-01-01 Epub Date: 2026-02-12 DOI: 10.1080/1750743X.2026.2626243

Ferda Akyuz Ozdemir, Dilek Yildirim, Melike Celik, Gulbeyaz Can

{"title":"Symptoms, symptom burden, and influencing factors in patients treated with Nivolumab.","authors":"Ferda Akyuz Ozdemir, Dilek Yildirim, Melike Celik, Gulbeyaz Can","doi":"10.1080/1750743X.2026.2626243","DOIUrl":"10.1080/1750743X.2026.2626243","url":null,"abstract":"Aim: Immune checkpoint inhibitors such as nivolumab are increasingly used in cancer treatment; however, their side effects may significantly affect patients' well-being and quality of life. This study aimed to determine symptom burden and influencing factors in patients receiving nivolumab immunotherapy.Material and method: This descriptive, cross-sectional study was conducted between October 2024 and January 2025 in a medical oncology clinic. A total of 53 patients receiving nivolumab participated. Data were collected through face-to-face interviews using a patient information form, a 40-item symptom assessment form, and the ECOG Performance Status Scale.Results: The most common symptoms were skin-related toxicities such as itching (18.9%) and dryness (20.8%), gastrointestinal problems like constipation (15.1%), and pulmonary symptoms such as fatigue (17%), cough (17%), and dyspnea (15.1%). Neurological symptoms like numbness and tingling in hands and feet (11.3%) were also reported. Among endocrine toxicities, hypothyroidism was observed in 20.8% of patients. Patients receiving concurrent chemotherapy had significantly higher symptom burden. Additionally, patients with adequate and balanced nutrition reported fewer and milder symptoms. Most patients had good performance status (81.1% fully active).Conclusions: Nivolumab-related symptoms are influenced by both treatment-related and individual lifestyle factors. Adequate nutrition and avoiding concurrent chemotherapy may help reduce symptom severity.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"25-35"},"PeriodicalIF":2.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12962607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146165350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0